Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLOVER HEALTH INVESTMENTS, CORP. /DECLOV · Entity 4419 | Director · 10% owner | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLOVER HEALTH INVESTMENTS, CORP. /DE
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,856,247 |
Last balance in matching sequence
After 2026-01-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-01-07 · Exercise / conversion · Acquired 1,655,949 · Balance 3,512,196 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. Row 2 · 2026-01-07 · Tax withholding · Disposed 1,655,949 · Balance 1,856,247 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 3,342,699 · Balance 0 F3: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021. F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 10,247,042 |
Reported balance
After 2026-01-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-07 · Exercise / conversion · Acquired 3,342,699 · Balance 10,247,042 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 8,591,093 |
Reported balance
After 2026-01-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-07 · Exercise / conversion · Disposed 1,655,949 · Balance 8,591,093 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectHeld by NJ Healthcare Investments, LLC | 72,084,543 |
Reported balance
Holding disclosure · report date 2026-01-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 72,084,543 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F4: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectHeld by Ceasar Clover, LLC | 11,500,000 |
Reported balance
Holding disclosure · report date 2026-01-07 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 11,500,000 F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F4: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
F2: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event.
F3: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021.
F4: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:08 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 1,655,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-26-000013 · wk-form4_1767992888.xml · derivative · entry 5 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,591,093 Underlying: Class A Common Stock · 1,655,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:08 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 3,342,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-26-000013 · wk-form4_1767992888.xml · derivative · entry 4 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,247,042 Underlying: Class A Common Stock · 3,342,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:08 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 3,342,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-26-000013 · wk-form4_1767992888.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 3,342,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.underlying: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:08 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Tax withholdingClass A Common Stock | 1,655,949 | $2.59 | $4,288,907.91 |
DisclosureSEC source: 0001801170-26-000013 · wk-form4_1767992888.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,247 F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:08 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 1,655,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001801170-26-000013 · wk-form4_1767992888.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,512,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 20:07 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | PurchaseClass A Common Stock | 31,980 | $2.17 | $69,396.60 |
DisclosureSEC source: 0001801170-25-000207 · wk-form4_1754683623.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,856,247 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.15 to $2.21, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:07 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | PurchaseClass A Common Stock | 415,000 | $2.24 | $929,600.00 |
DisclosureSEC source: 0001801170-25-000207 · wk-form4_1754683623.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,824,267 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.16 to $2.32, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:34 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 1,670,965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-25-000027 · wk-form4_1736544833.xml · derivative · entry 5 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,904,343 Underlying: Class A Common Stock · 1,670,965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:34 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-25-000027 · wk-form4_1736544833.xml · derivative · entry 4 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,575,308 Underlying: Class A Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:34 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-25-000027 · wk-form4_1736544833.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,342,699 Underlying: Class B Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.underlying: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:34 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Tax withholdingClass A Common Stock | 1,670,965 | $3.60 | $6,015,474.00 |
DisclosureSEC source: 0001801170-25-000027 · wk-form4_1736544833.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,409,267 F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:34 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 1,670,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001801170-25-000027 · wk-form4_1736544833.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,080,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:06 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | PurchaseClass A Common Stock | 531,700 | $1.88 | $999,596.00 |
DisclosureSEC source: 0001801170-24-000172 · wk-form4_1723579605.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,409,267 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $1.84 to $1.91, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:03 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | PurchaseClass A Common Stock | 877,567 | $1.14 | $1,000,426.38 |
DisclosureSEC source: 0001801170-24-000132 · wk-form4_1718913804.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,567 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $1.08 to $1.17, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 21:05 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 1,561,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-24-000039 · wk-form4_1704834283.xml · derivative · entry 5 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,232,610 Underlying: Class A Common Stock · 1,561,065 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2024, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,781,633 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,561,065 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 21:05 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-24-000039 · wk-form4_1704834283.xml · derivative · entry 4 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,793,675 Underlying: Class A Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2024, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,781,633 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,561,065 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 21:05 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-24-000039 · wk-form4_1704834283.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,685,397 Underlying: Class B Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.underlying: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 21:05 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Tax withholdingClass A Common Stock | 1,561,065 | $0.95 | $1,483,011.75 |
DisclosureSEC source: 0001801170-24-000039 · wk-form4_1704834283.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2024, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,781,633 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,561,065 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. Read SEC document |
| January 07, 2024 Filed Jan 9, 2024 21:05 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 1,561,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001801170-24-000039 · wk-form4_1704834283.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,561,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2024, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,781,633 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,561,065 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2023 Filed Apr 29, 2023 00:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 1,569,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-23-000261 · form4.xml · derivative · entry 5 Garipalli Vivek · CIK 0001839260 · Director · Executive Chairperson · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,450,977 Underlying: Class A Common Stock · 1,569,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2023, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,773,104 shares of the Issuer's Class B Common stock being delivered to the Reporting Person and 1,569,594 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2023 Filed Apr 29, 2023 00:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-23-000261 · form4.xml · derivative · entry 4 Garipalli Vivek · CIK 0001839260 · Director · Executive Chairperson · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,020,571 Underlying: Class A Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · derivative.exercise_price: On January 7, 2023, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,773,104 shares of the Issuer's Class B Common stock being delivered to the Reporting Person and 1,569,594 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.exercise_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F1 · derivative.expiration_date: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2023 Filed Apr 29, 2023 00:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-23-000261 · form4.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · Executive Chairperson · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,028,095 Underlying: Class B Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. F3 · derivative.underlying: Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021. Read SEC document |
| January 07, 2023 Filed Apr 29, 2023 00:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Tax withholdingClass A Common Stock | 1,569,594 | $1.01 | $1,585,289.94 |
DisclosureSEC source: 0000895345-23-000261 · form4.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · Executive Chairperson · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2023, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,773,104 shares of the Issuer's Class B Common stock being delivered to the Reporting Person and 1,569,594 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. Read SEC document |
| January 07, 2023 Filed Apr 29, 2023 00:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 1,569,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-23-000261 · form4.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · Executive Chairperson · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,569,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. F2 · shares: On January 7, 2023, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,773,104 shares of the Issuer's Class B Common stock being delivered to the Reporting Person and 1,569,594 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event. F1 · price: The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 02:51 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 3,342,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000730 · wf-form4_164195588944291.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,370,793 Underlying: Class B Common Stock · 3,342,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: On January 7, 2021, the Reporting Person was granted 16,713,491 RSUs, vesting in equal annual installments over five years, beginning on January 7, 2022, subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through each vesting date. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person upon vesting. F2 · derivative.expiration_date: On January 7, 2021, the Reporting Person was granted 16,713,491 RSUs, vesting in equal annual installments over five years, beginning on January 7, 2022, subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through each vesting date. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person upon vesting. F3 · derivative.underlying: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 02:51 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Tax withholdingClass B Common Stock | 1,664,825 | $3.16 | $5,260,847.00 |
DisclosureSEC source: 0001628280-22-000730 · wf-form4_164195588944291.xml · nonDerivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,677,873 Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 02:51 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass B Common Stock | 3,342,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-000730 · wf-form4_164195588944291.xml · nonDerivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantPerformance-based Restricted Stock Units · Derivative | 5,571,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 7 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,571,164 Underlying: Class B Common Stock · 5,571,164 shares Expires not disclosed F7 · derivative.exercise_price: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F7 · derivative.exercise_date: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F7 · derivative.expiration_date: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F1 · derivative.underlying: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantRestricted Stock Units · Derivative | 16,713,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 6 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,713,491 Underlying: Class B Common Stock · 16,713,491 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. F10 · derivative.exercise_date: The RSUs will vest in equal annual installments over five years, beginning on January 7, 2022, subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through each vesting date. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person upon vesting. F10 · derivative.expiration_date: The RSUs will vest in equal annual installments over five years, beginning on January 7, 2022, subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through each vesting date. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person upon vesting. F1 · derivative.underlying: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantPerformance-based Restricted Stock Units · Derivative | 7,164,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 5 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,164,581 Underlying: Class B Common Stock · 7,164,581 shares Expires not disclosed F7 · derivative.exercise_price: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F8 · price: Received in connection with the Business Combination in exchange for restricted stock units that will have settled for 3,464,373 shares of common stock of Legacy Clover. F7 · derivative.exercise_date: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F7 · derivative.expiration_date: Each performance-based restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. The PRSUs generally vest in five equal installments on January 7 of each of 2022, 2023, 2024, 2025 and 2026 respectively, provided that the applicable performance goal has been achieved by such date (and, if not, on the date the applicable performance goal is subsequently achieved), and are subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through the applicable vesting date. The applicable performance goal for each tranche will be satisfied if the Issuer's Class A Common Stock achieves a specified per share market price for such tranche for at least 90 consecutive calendar days. If the applicable performance goals have not been achieved by January 7, 2026, all unvested PRSUs will be forfeited. F1 · derivative.underlying: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass B Common Stock · Derivative | 2,062,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 4 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Caesar Clover, LLC Disclosed balance after: 2,062,265 Underlying: Class A Common Stock · 2,062,265 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F6 · price: Received in connection with the Business Combination in exchange for 997,191 shares of Class Z common stock of Legacy Clover. F1 · derivative.exercise_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC. Therefore, the Reporting Person may be deemed to share voting power and dispositive power over the shares held by these entities. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass B Common Stock · Derivative | 5,645,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 3 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Caesar Ventures, LLC Disclosed balance after: 5,645,934 Underlying: Class A Common Stock · 5,645,934 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F5 · price: Received in connection with the Business Combination in exchange for 2,730,044 shares of Class Z common stock of Legacy Clover. F1 · derivative.exercise_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC. Therefore, the Reporting Person may be deemed to share voting power and dispositive power over the shares held by these entities. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass B Common Stock · Derivative | 182,201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 2 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Titus Ventures, LLC Disclosed balance after: 182,201 Underlying: Class A Common Stock · 182,201 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F4 · price: Received in connection with the Business Combination in exchange for 88,102 shares of Class Z common stock of Legacy Clover. F1 · derivative.exercise_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC. Therefore, the Reporting Person may be deemed to share voting power and dispositive power over the shares held by these entities. Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 02:14 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass B Common Stock · Derivative | 75,694,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003159 · doc4.xml · derivative · entry 1 Garipalli Vivek · CIK 0001839260 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by NJ Healthcare Investments, LLC Disclosed balance after: 75,694,143 Underlying: Class A Common Stock · 75,694,143 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F2 · price: Received in connection with the Issuer's business combination (the "Business Combination") with Clover Health Investments, Corp. ("Legacy Clover") in accordance with the terms of the Agreement and Plan of Merger dated as of October 5, 2020, among the Issuer (f/k/a Social Capital Hedosophia Holdings Corp. III), Asclepius Merger Sub Inc., and Legacy Clover, as amended by that certain Amendment to the Agreement and Plan of Merger, dated as of December 8, 2020, in exchange for 36,601,265 shares of Class Z common stock of Legacy Clover. F1 · derivative.exercise_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC. Therefore, the Reporting Person may be deemed to share voting power and dispositive power over the shares held by these entities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.